Heartware Int'l (HTWR) Posts Smaller-than-Expected Q2 Loss

Heartware Int'l (NASDAQ: HTWR) reported Q2 EPS of ($0.29), $0.45 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $70.1 million versus the consensus estimate of $67.01 million.

"We are pleased to announce another encouraging quarterly performance, with record sales and more than 300 units in both the U.S. as well as international markets for the second consecutive quarter," said Doug Godshall, President and Chief Executive Officer. "More than 6,000 patients from 40 countries around the globe have received the HeartWare System as a treatment for their advanced heart failure, with patient support extending as long as seven years.

"In addition to our commercial efforts, we continue to make investments to advance our clinical trials, including enrolling the second phase of our destination therapy study in the U.S., moving toward completion of enrollment of our Japan trial and preparing to initiate the clinical evaluation of our next-generation MVAD® System," Godshall said. "As we continue to drive these programs forward, our highest internal priority remains addressing and remedying the observations raised by FDA following an inspection at our Miami Lakes, Florida facility earlier this year."

For earnings history and earnings-related data on Heartware Int'l (HTWR) click here.

You May Also Be Interested In